Idorsia holds its Annual General Meeting of Shareholders
Ad hoc announcement pursuant to Art. 53 LR
Read more:
Idorsia holds its Annual General Meeting of Shareholders
Ad hoc announcement pursuant to Art. 53 LR
Read more:
Idorsia holds its Annual General Meeting of Shareholders
DURHAM, N.C., April 14, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system and novel biodefense assets, today announced it plans to host an investor and media livestream event on Tuesday, April 19, 2022 at 10:30 AM Eastern Time to discuss the latest developments. The event will be broadcast at: https://vimeo.com/event/2027558/fc6de52c31
Read more:
Heat Biologics’ Announces Planned Investor and Media Livestream Event to Discuss Latest Developments
Dr. Oelke is a scientific co-founder of NexImmune and a pioneer in the field of artificial antigen presenting cell (aAPC) technology Dr. Oelke is a scientific co-founder of NexImmune and a pioneer in the field of artificial antigen presenting cell (aAPC) technology
Visit link:
NexImmune Promotes Mathias Oelke, Ph.D., To Chief Scientific Officer
L’ASSOMPTION, Quebec, April 14, 2022 (GLOBE NEWSWIRE) -- Terranueva Corporation (CSE: TEQ) ("Terranueva" or the "Company") is pleased to announce the results of its annual and special meeting of shareholders held on April 14, 2022. The shareholders approved, by a majority of votes, a resolution to elect the following directors: Sylvain Aird, Marc-André Aubé, Marianne Fortier-Landry, Gérard Landry, Jean-Luc Landry, Peter Polatos and Sylvain Tremblay. Also, the shareholders, by a majority of votes, proceeded with the appointment of PricewaterhouseCoopers LLP as auditors of the Corporation, as well as approved the Corporation’s Fixed Stock Option Plan in order to increase at 4,596,996 the maximum of common shares to be issued upon exercise of options, which represents 10% of the number of common share in the capital stock of Terranueva as of the record date of March 14, 2022.
See the original post:
Terranueva: Results of the Shareholders Meeting
IRVINE, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune conditions, and neurodegenerative disease, today announced that it will host its first R&D Day on Thursday, April 28, 2022, from 10 a.m. to 12 p.m. ET (7 a.m. to 9 a.m. PT). Members of Eledon’s senior management team will be joined by four leading experts for a deep dive on the company’s investigational drug, tegoprubart, and the promise of CD40 Ligand targeted immunotherapy for the treatment of amyotrophic lateral sclerosis, kidney transplantation, islet cell transplantation, and IgA nephropathy.
Visit link:
Eledon to Host Virtual R&D Day on Thursday, April 28, 2022
Scientific Advisory Board strengthens LianBio’s mission of bringing novel therapeutics to Greater China and Asia Scientific Advisory Board strengthens LianBio’s mission of bringing novel therapeutics to Greater China and Asia
Go here to read the rest:
LianBio Announces Formation of Scientific Advisory Board
UNIONDALE, N.Y., April 14, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced participation in an upcoming investment conference.
Read more from the original source:
Angion Announces Participation in Upcoming Investment Conference
LEXINGTON, Mass., April 14, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens, announced today that it issued inducement awards to twenty-eight new employees.
Read more:
T2 Biosystems Reports Granting of Inducement Award
SOUTH SAN FRANCISCO, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that John A. Scarlett, M.D. is retiring from its board of directors, effective when his current term expires at the company’s next annual meeting of stockholders, which is currently scheduled to be held on June 15, 2022.
Read more:
CytomX Therapeutics Announces Retirement of John A. Scarlett, M.D. from Board of Directors
CAMBRIDGE, Mass., April 14, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Dr. Christopher Slapak, Chief Medical Officer for Vor Bio plans to retire. The Vor Bio clinical team is fully resourced and continues to actively recruit patients into VBP101, the Company’s Phase 1/2a first-in-human study of VOR33 in patients with AML who are at high risk of relapse. An executive search to replace Dr. Slapak is underway.
Go here to see the original:
Vor Bio Announces Retirement of Chief Medical Officer